Here is the design of a clinical trial:

Official Title: How Often Can Optimal Post Percutaneous Coronary Intervention (PCI) Fractional Flow Reserve (FFR) Results be Achieved? - a Randomised Controlled Trial of FFR Targeted PCI (the Target FFR Study)

Included conditions:
- Coronary Artery Disease
- Coronary Stenosis

Study Armgroups:
- {'label': 'PIOS Intervention Group', 'type': 'EXPERIMENTAL', 'description': 'Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is \\<0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback will be performed during a standard peripheral intravenous adenosine infusion (140mcg/kg/min).\n\nThe operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result.', 'interventionNames': ['Procedure: P.I.O.S.', 'Diagnostic Test: Pre and post-PCI coronary physiology measurements']}
- {'label': 'Control Group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.', 'interventionNames': ['Diagnostic Test: Pre and post-PCI coronary physiology measurements']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'P.I.O.S.', 'description': 'Physiologically-Guided Incremental Optimisation Strategy', 'armGroupLabels': ['PIOS Intervention Group']}
- {'type': 'DIAGNOSTIC_TEST', 'name': 'Pre and post-PCI coronary physiology measurements', 'description': 'Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator', 'armGroupLabels': ['Control Group', 'PIOS Intervention Group']}

Primary Outcomes:
- {'measure': 'The proportion of patients with a final post-PCI FFR result ≥0.90', 'description': 'The proportion of patients with a final post-PCI FFR result ≥0.90 will be compared between the randomised groups', 'timeFrame': '1 day'}

Please estimate the sample size based on the assumption: 
A sample size of 130 patients per group would be required to have 90% power to detect a 20% difference between groups at the 5% significance level.
2.6
        Pilot data, power, and sample size calculation
        Pilot data from 50 patients who underwent postâPCI FFR assessment at our institution revealed that an initial postâPCI FFR result â¥0.90 was achieved in only 16/50 (32%). Additional optimization measures (further postdilation, stenting or both) were attempted in just nine patients (18%). Initial postâPCI FFR increased from a median of 0.83 (0.80â0.86) to a final FFR of 0.88 (0.86â0.89) in these patients. The results of pullback measurements performed in all 50 vessels, however, revealed at least one target for additional optimization measures was present in up to 40% of patients (HTG â¥0.05 in 19/50 (38%); focal stepâup â¥0.05 either proximal or distal to the stented segment in 21/50 (42%). It is hypothesized that systematically applying the PIOS intervention will result in a 20% absolute increase in the proportion of patients with a final postâPCI FFR â¥0.90 compared to the control group. A sample size of 130 patients per group would be required to have 90% power to detect a 20% difference between groups at the 5% significance level; therefore, 260 patients will be randomized. Patients presenting with stable angina or NSTEMI who attend our institution for diagnostic coronary angiography proceed to PCI during the same procedure in approximately 40% of cases. It is therefore estimated that approximately 650 patients will be enrolled in the study in order to randomize 260 patients following their standardâofâcare PCI.